CYBERLOQ TECHNOLOGIES, INC.
A financially distressed micro-cap technology firm with negligible recent revenue, significant accumulated debt, and heavy reliance on external capital injections to sustain operations.
A financially distressed micro-cap technology firm with negligible recent revenue, significant accumulated debt, and heavy reliance on external capital injections to sustain operations.
The stock represents a deep value play for investors willing to bet on asset-backed turnaround scenarios given the $1.6M in net fixed assets. The company has successfully raised over $7M in paid-in capital, providing a runway to potentially execute a strategic pivot or product launch. Micro-cap status offers high volatility potential with limited float for aggressive short-term traders seeking asymmetric upside.
The negative shareholder equity of nearly -$1M and accumulated deficit of -$8.6M indicate a fundamentally insolvent business model requiring continuous capital raises. Zero revenue generation over three years demonstrates an inability to monetize its asset base or service offerings effectively. The current liability structure of $2.8M significantly outweighs current assets, creating an imminent threat of default or restructuring.
CYBERLOQ TECHNOLOGIES, INC. (CLOQ) is a micro-cap technology entity operating with minimal revenue generation in the last three years. The company holds significant deferred equity and fixed assets but currently reports substantial accumulated deficits and negative operational cash flows. Investors should note the firm's structural balance sheet issues while assessing its potential for future operational scaling.
The company's recent financial performance is characterized by a net loss of $0.9M driven entirely by operating expenses exceeding minimal revenue of $15k. Cash balance has contracted from $307k to $283k due to negative operating cash flows partially offset by significant financing inflows of $1.1M. The enterprise remains in a precarious position where continued survival depends on external equity issuance rather than internal cash generation.
The technology sector typically rewards companies with scalable SaaS models or proprietary IP that generate recurring revenue streams, which CLOQ currently lacks. Micro-cap tech firms often struggle with high burn rates during the pre-revenue phase, making profitability a long-term horizon event. Regulatory scrutiny on tax expenses and accounting treatments is higher for entities with significant non-cash adjustments and deferred revenues.
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $2.7K | $16.0K | $15.0K |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $2.7K | $16.0K | $15.0K |
| Operating Expenses | $685.0K | $383.2K | $767.9K |
| Operating Income | $-682.3K | $-367.2K | $-752.9K |
| G&A | $24.8K | $18.9K | $51.9K |
| Stock-Based Comp | $350.6K | $5.0K | $79.0K |
| D&A | — | $0 | $0 |
| Other OpEx | $660.2K | $364.3K | $716.0K |
| Non-Operating Income | $0 | $0 | $0 |
| Pre-Tax Income | $-682.3K | $-367.2K | $-752.9K |
| Income Tax | $296.7K | $659.3K | $236.5K |
| Continuing Ops | $-979.0K | $-1.0M | $-989.5K |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-979.0K | $-1.0M | $-989.5K |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-979.0K | $-1.0M | $-989.5K |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $57.9K | $361.7K | $289.8K |
| Accounts Receivable | — | $10.0K | — |
| Other Current Assets | — | $351.7K | — |
| Long-Term Assets | $283.2K | $1.1M | $1.6M |
| PP&E (Net) | $283.2K | $1.1M | $1.6M |
| Other LT Assets | $0 | $0 | $0 |
| Total Assets | $341.1K | $1.5M | $1.8M |
| Current Liabilities | $293.8K | $991.0K | $2.8M |
| Deferred Revenue | $0 | $0 | $0 |
| Other Current Liab | $293.8K | $991.0K | $2.8M |
| Long-Term Liabilities | $30.4K | $30.4K | $30.4K |
| Total Liabilities | $324.1K | $1.0M | $2.8M |
| Shareholders' Equity | $17.0K | $437.2K | $-988.5K |
| Paid-In Capital | $7.0M | $8.5M | $7.4M |
| Retained Earnings | $-7.2M | $-8.3M | $-8.6M |
| Treasury Stock | $50.0K | $50.0K | $50.0K |
| Total L&E | $341.1K | $1.5M | $1.8M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-979.0K | $-1.0M | $-989.5K |
| Non-Cash Adjustments | $551.7K | $551.6K | $149.2K |
| Working Capital Changes | $55.4K | $134.1K | $125.1K |
| Cash from Operations | $-372.0K | $-340.8K | $-715.1K |
| Cash from Investing | $-283.2K | $-805.4K | $-456.0K |
| Share Buybacks | $50.0K | — | — |
| Cash from Financing | $605.0K | $1.4M | $1.1M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-50.2K | $303.1K | $-24.3K |
| Beginning Cash | $54.3K | $4.1K | $307.2K |
| Ending Cash | $4.1K | $307.2K | $282.9K |
The company currently lacks diversified revenue streams as total revenue has been near zero since 2022. Operational expenses are dominated by general and administrative costs rather than product sales or service contracts. The financial profile suggests a pre-revenue entity focused on asset accumulation or early-stage R&D without commercial traction.
Severe liquidity crisis with negative operating cash flow of -$0.7M and total liabilities exceeding total assets by over $1M. Persistent net losses of -$1M annually have created an accumulated deficit of nearly -$9M threatening solvency. Lack of revenue generation for three consecutive years prevents organic growth and creates heavy dependency on dilutive financing. High income tax expense relative to negligible profit indicates potential accounting complexities or aggressive recognition policies.
Possesses substantial long-term fixed assets valued at $1.6M which could indicate proprietary infrastructure or technology holdings. Maintains a significant paid-in capital base of $7.4M suggesting strong historical investor support or equity financing history. Operates with zero cost of revenue, indicating potential for high-margin services once commercial operations are established.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.